Pfizer to Host Webinar: “Understanding PAXLOVID: An oral treatment authorized for COVID-19”

PAXLOVID is contraindicated in patients with a history of clinically significant hypersensitivity reactions (eg, toxic epidermal necrolysis [TEN] or Stevens-Johnson syndrome) to its active ingredients (nirmatrelvir or ritonavir) or any other components of the product.

PAXLOVID is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions:

    • Alpha1-adrenoreceptor antagonist: alfuzosin
    • Analgesics: pethidine, propoxyphene

Important Safety Information, including additional contraindications, continued below.

You’re invited to join a webinar about PAXLOVID.

PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

The webinar will include information about clinical management and an overview of SARS-CoV-2, followed by a Q&A session and post-event poll.

Choose your registration date now:

Tuesday, March 22
12:00PM EST – Register for this Time

Tuesday, March 22
7:00PM EST – Register for this Time